NasdaqGS - Nasdaq Real Time Price • USD
Gossamer Bio, Inc. (GOSS)
As of 3:03 PM EDT. Market Open.
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 9 | 9 | 10 | 10 |
| Avg. Estimate | -0.19 | -0.19 | -0.76 | -0.7 |
| Low Estimate | -0.23 | -0.23 | -0.94 | -1 |
| High Estimate | -0.15 | -0.14 | -0.59 | -0.46 |
| Year Ago EPS | -0.52 | -0.45 | -1.18 | -0.76 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 7 | 7 | 8 | 8 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.53 | -0.49 | -0.26 | -0.21 |
| EPS Actual | -0.52 | -0.45 | -0.21 | -0.21 |
| Difference | 0.01 | 0.04 | 0.05 | 0 |
| Surprise % | 1.90% | 8.20% | 19.20% | 0.00% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.19 | -0.19 | -0.76 | -0.7 |
| 7 Days Ago | -0.19 | -0.19 | -0.76 | -0.7 |
| 30 Days Ago | -0.18 | -0.18 | -0.74 | -0.69 |
| 60 Days Ago | -0.19 | -0.19 | -0.78 | -0.7 |
| 90 Days Ago | -0.19 | -0.19 | -0.79 | -0.72 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | GOSS | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 63.50% | -- | -- | 1.50% |
| Next Qtr. | 57.80% | -- | -- | 12.10% |
| Current Year | 35.60% | -- | -- | 4.40% |
| Next Year | 7.90% | -- | -- | 13.20% |
| Next 5 Years (per annum) | 5.20% | -- | -- | 10.97% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Maintains | Piper Sandler: Overweight to Overweight | 3/27/2024 |
| Maintains | Goldman Sachs: Buy to Buy | 3/6/2024 |
| Reiterates | Wedbush: Outperform to Outperform | 3/6/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 3/6/2024 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 1/8/2024 |
| Reiterates | Wedbush: Outperform to Outperform | 12/19/2023 |
Related Tickers
QURE uniQure N.V.
4.5800
+0.88%
BDTX Black Diamond Therapeutics, Inc.
5.69
+11.31%
STOK Stoke Therapeutics, Inc.
12.25
+4.79%
CLNN Clene Inc.
0.3359
-3.06%
ALEC Alector, Inc.
5.25
+9.04%
FGEN FibroGen, Inc.
1.0450
+2.45%
KZR Kezar Life Sciences, Inc.
0.8092
+2.43%
AKRO Akero Therapeutics, Inc.
19.72
+4.17%
DTIL Precision BioSciences, Inc.
9.73
+0.10%
FOLD Amicus Therapeutics, Inc.
10.25
+0.74%